Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

Pfizer is reportedly exploring partnerships with private equity firms to help fund the development and commercialization of its once-monthly weight-loss drug. By seeking external capital, the pharmaceutical giant aims to manage the significant costs associated with late-stage clinical trials and the massive manufacturing scale-up required for the competitive obesity treatment market. This strategic move reflects the company's effort to accelerate its pipeline while mitigating financial risk in a high-stakes sector.